MRSN

Companies
NASDAQ
Mersana Therapeutics Inc.
Health Care
Price Chart
Overview

About MRSN

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Market Cap
$261.9M
Volume
1.2M
Avg. Volume
964.9K
P/E Ratio
-0.55714285
Dividend Yield
0.00%
Employees
189.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.96
High Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for MRSN.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, MRSN shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$261.9M
Volume1.2M
P/E Ratio-0.56
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 15, 2025

PortfolioPilot Analysis

Get AI-powered insights on how MRSN fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025